PaxMedica (NASDAQ:PXMD – Get Free Report) is expected to issue its resultson Wednesday, June 3rd. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.
PaxMedica Stock Performance
Shares of NASDAQ:PXMD opened at $0.00 on Wednesday. The stock has a market capitalization of $7,918.40, a price-to-earnings ratio of 0.00 and a beta of -0.99. PaxMedica has a 52-week low of $0.00 and a 52-week high of $0.02.
About PaxMedica
PaxMedica, Inc is a clinical‐stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation.
The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges.
Featured Stories
- Five stocks we like better than PaxMedica
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
